• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Women's perspectives on counseling about risks for medication-induced birth defects.女性对药物性出生缺陷风险咨询的看法。
Birth Defects Res A Clin Mol Teratol. 2010 Jan;88(1):64-9. doi: 10.1002/bdra.20618.
2
Perspectives of primary care clinicians on teratogenic risk counseling.基层医疗临床医生对致畸风险咨询的看法。
Birth Defects Res A Clin Mol Teratol. 2009 Oct;85(10):858-63. doi: 10.1002/bdra.20599.
3
Utility of reproductive life plans in identification of potentially teratogenic medication use: A pilot study.生殖生活计划在识别潜在致畸药物使用方面的效用:一项试点研究。
Birth. 2018 Mar;45(1):50-54. doi: 10.1111/birt.12318. Epub 2017 Oct 20.
4
Clinical decision support to promote safe prescribing to women of reproductive age: a cluster-randomized trial.临床决策支持促进育龄妇女安全处方:一项集群随机试验。
J Gen Intern Med. 2012 Jul;27(7):831-8. doi: 10.1007/s11606-012-1991-y.
5
Counseling about medication-induced birth defects with clinical decision support in primary care.在基层医疗中使用临床决策支持进行药物引起的出生缺陷咨询。
J Womens Health (Larchmt). 2013 Oct;22(10):817-24. doi: 10.1089/jwh.2013.4262. Epub 2013 Aug 9.
6
High-Risk Medication Prescriptions in Primary Care for Women Without Documented Contraception.初级保健中未记录避孕措施的女性的高危药物处方。
J Am Board Fam Med. 2019 Jul-Aug;32(4):474-480. doi: 10.3122/jabfm.2019.04.180281.
7
Provision of potentially teratogenic medications to female veterans of childbearing age.向育龄期女退役军人提供潜在致畸药物。
Med Care. 2010 Sep;48(9):834-42. doi: 10.1097/MLR.0b013e3181e57946.
8
Women's perceptions of discussions about gestational weight gain with health care providers during pregnancy and postpartum: a qualitative study.孕期及产后女性对与医疗保健人员讨论孕期体重增加情况的看法:一项定性研究
BMC Pregnancy Childbirth. 2017 Mar 24;17(1):97. doi: 10.1186/s12884-017-1257-0.
9
Providing contraception for women taking potentially teratogenic medications: a survey of internal medicine physicians' knowledge, attitudes and barriers.为正在服用潜在致畸药物的女性提供避孕措施:内科医生知识、态度和障碍的调查。
J Gen Intern Med. 2010 Apr;25(4):291-7. doi: 10.1007/s11606-009-1215-2. Epub 2010 Jan 20.
10
The critical need for clinical decision support systems for identification and management of teratogenic medications.临床决策支持系统对于识别和管理致畸药物的迫切需求。
J Am Pharm Assoc (2003). 2019 Mar-Apr;59(2S):S18-S20. doi: 10.1016/j.japh.2018.12.011. Epub 2019 Feb 6.

引用本文的文献

1
Special Considerations for Women of Reproductive Age on Anticoagulation.生育年龄妇女抗凝的特殊考虑。
J Gen Intern Med. 2022 Aug;37(11):2803-2810. doi: 10.1007/s11606-022-07528-y. Epub 2022 May 31.
2
"I know my body better than you:" patient focus groups to inform a decision aid on oral corticosteroid use during pregnancy.“我比你更了解我的身体”:以患者为中心的焦点小组为妊娠期口服皮质类固醇使用决策辅助提供信息。
Pharmacoepidemiol Drug Saf. 2021 Apr;30(4):451-461. doi: 10.1002/pds.5183. Epub 2020 Dec 22.
3
A Qualitative Study of Pregnant Women's Perspectives on Antibiotic Use for Mom and Child: Implications for Developing Tailored Health Education Interventions.一项关于孕妇对母婴使用抗生素看法的定性研究:对制定针对性健康教育干预措施的启示
Antibiotics (Basel). 2020 Oct 15;9(10):704. doi: 10.3390/antibiotics9100704.
4
Perceptions of the Value of Clinical Pharmacy Medication Review for Women During Early Pregnancy.孕妇早期对临床药学药物评估价值的认知。
J Manag Care Spec Pharm. 2020 Oct;26(10):1301-1308. doi: 10.18553/jmcp.2020.26.10.1301.
5
True Choice in Reproductive Care: Using Cultural Humility and Explanatory Models to Support Reproductive Justice in Primary Care.生殖护理中的真正选择:在初级保健中运用文化谦逊和解释模型来支持生殖公正。
J Gen Intern Med. 2021 May;36(5):1395-1399. doi: 10.1007/s11606-020-06245-8. Epub 2020 Sep 24.
6
Pharmacists and Contraception in the Inpatient Setting.住院环境中的药剂师与避孕
Pharmacy (Basel). 2020 May 9;8(2):82. doi: 10.3390/pharmacy8020082.
7
Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects.优化妊娠期药物安全性信号的反应:以多替拉韦和神经管缺陷为例。
J Int AIDS Soc. 2019 Jul;22(7):e25352. doi: 10.1002/jia2.25352.
8
Improving Safe Use of Medications During Pregnancy: The Roles of Patients, Physicians, and Pharmacists.改善孕期用药安全:患者、医生和药师的作用。
Qual Health Res. 2017 Nov;27(13):2071-2080. doi: 10.1177/1049732317732027. Epub 2017 Oct 3.
9
Making Decisions About Medication Use During Pregnancy: Implications for Communication Strategies.孕期用药决策:对沟通策略的启示
Matern Child Health J. 2018 Jan;22(1):92-100. doi: 10.1007/s10995-017-2358-0.
10
Why women do not ask for information on preconception health? A qualitative study.为何女性不寻求孕前健康信息?一项定性研究。
BMC Pregnancy Childbirth. 2017 Jan 5;17(1):5. doi: 10.1186/s12884-016-1198-z.

本文引用的文献

1
The effect of preconception counselling on lifestyle and other behaviour before and during pregnancy.孕前咨询对怀孕前及孕期生活方式和其他行为的影响。
Womens Health Issues. 2008 Nov-Dec;18(6 Suppl):S117-25. doi: 10.1016/j.whi.2008.09.003.
2
Computerized counseling for folate knowledge and use: a randomized controlled trial.叶酸知识与使用的计算机化咨询:一项随机对照试验。
Am J Prev Med. 2008 Dec;35(6):568-71. doi: 10.1016/j.amepre.2008.06.034.
3
Preconception counselling for women with epilepsy to reduce adverse pregnancy outcome.为癫痫女性提供孕前咨询以减少不良妊娠结局。
Cochrane Database Syst Rev. 2008 Jul 16(3):CD006645. doi: 10.1002/14651858.CD006645.pub2.
4
Pre-conception counselling in primary care: prevalence of risk factors among couples contemplating pregnancy.初级保健中的孕前咨询:计划怀孕夫妇中危险因素的患病率。
Paediatr Perinat Epidemiol. 2008 May;22(3):280-7. doi: 10.1111/j.1365-3016.2008.00930.x.
5
Becoming pregnant: exploring the perspectives of women living with diabetes.怀孕:探索糖尿病女性患者的观点。
Br J Gen Pract. 2008 Mar;58(548):184-90. doi: 10.3399/bjgp08X277294.
6
Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women.为育龄妇女开具可能致畸药物时的避孕及妊娠情况记录。
Ann Intern Med. 2007 Sep 18;147(6):370-6. doi: 10.7326/0003-4819-147-6-200709180-00006.
7
Recommendations to improve preconception health and health care--United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care.改善孕前健康及医疗保健的建议——美国。疾病控制与预防中心/美国毒物与疾病登记署孕前保健工作组及孕前保健特别小组报告。
MMWR Recomm Rep. 2006 Apr 21;55(RR-6):1-23.
8
Three approaches to qualitative content analysis.定性内容分析的三种方法。
Qual Health Res. 2005 Nov;15(9):1277-88. doi: 10.1177/1049732305276687.
9
Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making.孕妇使用抗抑郁药:风险认知评估、循证咨询的有效性及决策的决定因素
Arch Womens Ment Health. 2005 Nov;8(4):214-20. doi: 10.1007/s00737-005-0094-8. Epub 2005 Jun 17.
10
Prescription drug use in pregnancy.孕期处方药的使用。
Am J Obstet Gynecol. 2004 Aug;191(2):398-407. doi: 10.1016/j.ajog.2004.04.025.

女性对药物性出生缺陷风险咨询的看法。

Women's perspectives on counseling about risks for medication-induced birth defects.

作者信息

Santucci Aimee K, Gold Melanie A, Akers Aletha Y, Borrero Sonya, Schwarz Eleanor Bimla

机构信息

Center for Research on Health Care, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

出版信息

Birth Defects Res A Clin Mol Teratol. 2010 Jan;88(1):64-9. doi: 10.1002/bdra.20618.

DOI:10.1002/bdra.20618
PMID:19637252
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2806515/
Abstract

PURPOSE

This qualitative study explored women's experiences with counseling about medication-induced birth defects, as well as how and when they would like to receive information on medication-induced birth defects from their health care providers (HCPs).

METHODS

We conducted four focus groups with 36 women of reproductive age (18-45 years old) in Pittsburgh, Pennsylvania. Twenty-one women were using medications to treat a chronic health condition, and two were pregnant. Content analysis was performed by three independent coders using a grounded theory approach. Discrepancies were resolved by consensus.

RESULTS

Women reported depending on their HCPs for information about the risks of teratogenic effects of medications on a pregnancy, but felt the information they had been provided was not always comprehensive. Women want HCPs to initiate discussions about potentially teratogenic medications at the time the medications are prescribed, regardless of whether the woman is sexually active or planning a pregnancy. Women want clear information about all potential outcomes for a fetus. Factors women reported as being critical to effective teratogenic risk counseling included privacy, sufficient time to discuss the topic, and a trusting relationship with their HCP.

CONCLUSIONS

Women of reproductive age think that providing information about the possible teratogenic effects of medications could be improved by routine discussions of teratogenic risks at the time medications are prescribed.

摘要

目的

本定性研究探讨了女性在接受药物致畸性咨询方面的经历,以及她们希望如何以及何时从医疗保健提供者(HCPs)处获得有关药物致畸性的信息。

方法

我们在宾夕法尼亚州匹兹堡对36名育龄女性(18 - 45岁)进行了四个焦点小组访谈。21名女性正在使用药物治疗慢性健康状况,其中两名怀孕。由三名独立编码员采用扎根理论方法进行内容分析。通过共识解决分歧。

结果

女性报告称依赖医疗保健提供者获取有关药物对妊娠致畸风险的信息,但觉得所提供的信息并不总是全面的。女性希望医疗保健提供者在开药时就开始讨论潜在致畸药物,无论该女性是否有性行为或正在计划怀孕。女性希望获得关于胎儿所有潜在结局的清晰信息。女性报告称对有效的致畸风险咨询至关重要的因素包括隐私、有足够时间讨论该话题以及与医疗保健提供者的信任关系。

结论

育龄女性认为,通过在开药时常规讨论致畸风险,可以改善关于药物可能致畸作用的信息提供。